重组人血管内皮抑制素(恩度)联合化疗治疗骨肉瘤的临床研究

目的骨肉瘤是好发于青少年的恶性肿瘤,预后较差。目前的化疗效果不能提高患者的5年生存率。近年来内皮抑素抑制肿瘤血管生成的作用受到重视,文中评价重组人血管内皮抑制素(恩度)治疗骨肉瘤的近期疗效和安全性。方法明确诊断为骨肉瘤的患者随机分为试验组(即恩度组)和对照组。试验组采用恩度联合化疗治疗,对照组单用化疗药物治疗,观察2组的临床受益率、生活质量评分和不良反应。结果 22例骨肉瘤患者纳入本研究。试验组和对照组的临床受益率分别为100%和71.4%,不良反应差异无统计学意义(P>0.05)。无预期以外的不良事件发生。结论初步研究结果表明,恩度对骨肉瘤显示出一定的抗肿瘤活性,安全性较好,值得进一步研究。

A clinical observation of rh-endostatin(endostar) combined with chemotherapy for osteosarcoma

Objective Osteosarcoma is a malignant tumor which frequently occurs in adolescents.It has a poor prognosis,and chemotherapy cannot improve the five-year survival of the patients.This study was to evaluate the short-term efficacy and safety of rh-endostatin(endostar) in the treatment of osteosarcoma.Methods We assigned 17 patients with confirmed osteosarcoma to an experimental group(n=10) and a control group(n=7),the former treated with endostar in combination with chemotherapy,and the latter by chemotherapy only.We observed and compared the clinical benefit response(CBR),quality of life scores and adverse reactions in the two groups.Results The CBR rates were 100% and 71.4% in the experimental and the control group,respectively.There were no statistically significant differences in adverse effects between the two groups(P>0.05),nor were there any unexpected adverse events.Conclusion Endostar exhibited anti-tumor activity with high clinical benefit response for osteosarcoma patients.